Fortress Biotech
2 Gansevoort Street
9th Floor
New York
New York
10014
United States
Tel: 781-652-4500
Website: http://www.fortressbiotech.com/
Email: info@fortressbiotech.com
About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies, also known as Fortress Companies. Additionally, Fortress recently acquired a controlling interest in National Holdings Corporation (NASDAQ: NHLD), a diversified independent brokerage company (together with its subsidiaries, “NHLD”). In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies achieve their goals. Fortress and the Fortress Companies may seek licensings, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support their research and development programs.
LEADERSHIP:
CEO: Lindsay A. Rosenwald
CFO: Robyn Hunter
223 articles about Fortress Biotech
-
Fortress Biotech to Participate in 36th Annual ROTH Conference
3/12/2024
Fortress Biotech, Inc. today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in a fireside chat at the 36th Annual ROTH Conference on Monday, March 18, 2024, at 2:00 p.m. PT.
-
Fortress Biotech and Cyprium Therapeutics Announce $4.1 Million Grant from NINDS to Further Development of AAV-ATP7A Gene Therapy for Menkes Disease
3/4/2024
Cyprium Therapeutics, Inc. today announced that the National Institute of Neurological Disorders and Stroke (“NINDS”) of the National Institutes of Health (“NIH”) has awarded a three-year grant totaling approximately $4.1 million to the Research Institute at Nationwide Children’s Hospital.
-
Fortress Biotech Announces Closing of $11 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
1/3/2024
Fortress Biotech, Inc. announced the closing of its previously announced registered direct offering.
-
Cyprium Therapeutics, a Fortress Biotech Subsidiary Company, Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease
12/6/2023
Cyprium Therapeutics, Inc. (“Cyprium”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary company, today announced that it executed an Assignment and Assumption Agreement (the “Agreement”) with Sentynl Therapeutics, Inc.
-
Fortress Biotech Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
11/14/2023
Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2023.
-
Fortress Biotech Announces Closing of $10.0 Million Public Offering
11/14/2023
Fortress Biotech, Inc. announced the closing of its previously announced public offering of an aggregate of 5,885,000 units, consisting of one share of common stock and one warrant to purchase one share of common stock, at a public offering price of $1.70 per unit.
-
Fortress Biotech Announces Pricing of $10.0 Million Public Offering
11/10/2023
Fortress Biotech, Inc. today announced the pricing of its public offering of an aggregate of 5,885,000 units, at a public offering price of $1.70 per unit, consisting of (i) one share of common stock.
-
Fortress Biotech Announces Launch of Proposed Public Offering - November 09, 2023
11/9/2023
Fortress Biotech, Inc. announced that it has commenced a public offering, subject to market and other conditions, to offer and sell units, consisting of one share of common stock and one warrant to purchase one share of common stock.
-
Fortress Biotech Announces Reverse Stock Split - October 09, 2023
10/9/2023
Fortress Biotech, Inc., an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding common stock.
-
Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference
10/5/2023
Fortress Biotech, Inc. today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the ROTH MKM 2023 Healthcare Opportunities Conference in New York City on Thursday, October 12, 2023.
-
Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference
9/7/2023
Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 11:30 a.m. ET.
-
Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
8/14/2023
Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) today announced financial results and recent corporate highlights for the second quarter ended June 30, 2023.
-
Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023
8/3/2023
Fortress Biotech, Inc. today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the BTIG Virtual Biotechnology Conference on Tuesday, August 8, 2023 at 12:00 PM ET.
-
Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States
6/29/2023
Urica Therapeutics, Inc. today announced topline data from the Phase 1 clinical trial evaluating dotinurad in healthy volunteers in the United States (“U.S.”).
-
Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program
6/15/2023
Helocyte, Inc., a subsidiary company of Fortress Biotech, Inc., announced that the National Cancer Institute has awarded a $3.22 million grant to City of Hope for clinical studies of Triplex, a cytomegalovirus vaccine being developed by Helocyte and City of Hope.
-
Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
5/15/2023
Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced financial results and recent corporate highlights for the first quarter ended March 31, 2023.
-
Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights
3/30/2023
Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) today announced financial results and recent corporate highlights for the full-year ended December 31, 2022.
-
Fortress Biotech to Participate in Two March 2023 Investor Conferences
3/7/2023
Fortress Biotech, Inc. today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in two investor conferences in March 2023.
-
Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
2/16/2023
Helocyte, Inc. announced that data from a Phase 1 pilot trial evaluating the potential safety, immunological response and efficacy of the cytomegalovirus vaccine Triplex to enhance CMV protective immunity in immunosuppressed recipients of allogeneic hematopoietic cell transplants will be presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, taking place February 15-19, 2023, in Orlando, Florida.
-
Study Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe & Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with Triplex
2/15/2023
Helocyte, Inc. announced that data from a Phase 1 pilot study published in the American Journal of Hematology demonstrated the feasibility, safety, immunological response and potential efficacy associated with vaccination of a hematopoietic cell transplant donor with the cytomegalovirus vaccine Triplex to enhance protective CMV-specific T cells in immunosuppressed recipients of allogeneic HCT.